Johnson & Johnson (JNJ) Expected to Post Quarterly Earnings on Tuesday

Key Points

• Q3 2026 earnings are expected October 13 before the market opens. Analysts forecast EPS of $2.75 and revenue of approximately $25.36 billion; Johnson & Johnson’s full-year EPS guidance is $11.60–$11.75.
• In the prior quarter, J&J beat expectations with $2.90 EPS and $25.31 billion in revenue, while quarterly revenue increased 6.6% year over year.
• Patent-expiration risks remain a key investor concern. Analysts maintain a “Moderate Buy” consensus with an average price target of $276.09, but potential 2027 revenue exposure of about $4 billion and recent insider selling weigh on sentiment.

Johnson & Johnson (NYSE:JNJ - Get Free Report) will likely be posting its Q3 2026 results before the market opens on Tuesday, October 13th. Analysts expect Johnson & Johnson to post earnings of $2.75 per share and revenue of $25.3563 billion for the quarter. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Investors can check the company's upcoming Q3 2026 earning report page for the latest details on the call scheduled for Tuesday, October 13, 2026 at 8:30 AM ET.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.Johnson & Johnson's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.77 EPS. On average, analysts expect Johnson & Johnson to post $12 EPS for the current fiscal year and $13 EPS for the next fiscal year.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $252.90 on Tuesday. The firm has a market cap of $609.45 billion, a P/E ratio of 29.30, a P/E/G ratio of 2.52 and a beta of 0.21. Johnson & Johnson has a fifty-two week low of $182.94 and a fifty-two week high of $281.07. The business's 50 day moving average price is $266.10 and its 200-day moving average price is $248.51. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were issued a $1.34 dividend. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson's payout ratio is 62.11%.

Analyst Ratings Changes

JNJ has been the subject of several research reports. Bank of America restated a "neutral" rating and issued a $278.00 price objective on shares of Johnson & Johnson in a report on Tuesday, September 29th. Stifel Nicolaus set a $260.00 target price on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Guggenheim boosted their price target on shares of Johnson & Johnson from $270.00 to $287.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Citigroup increased their price target on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a "buy" rating in a research note on Monday. Finally, JPMorgan Chase & Co. raised their price objective on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $276.09.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Diversification and defensive demand support JNJ: Johnson & Johnson’s pharmaceutical, medical-device and consumer-health businesses provide multiple sources of revenue. Demand for healthcare products may remain relatively resilient during an economic downturn, supporting the company’s dividend appeal. Looking for a Dividend Stock That Can Weather a Downturn? Start With Johnson & Johnson.
• Positive Sentiment: Growth profile compares favorably with Pfizer: Analysts point to JNJ’s diversified portfolio, new product launches and sales growth as advantages over Pfizer, although Pfizer offers a lower valuation and higher dividend yield. Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
• Neutral Sentiment: Investors are focused on the October 13 earnings report: JNJ previously exceeded quarterly EPS and revenue expectations, and management’s full-year 2026 EPS guidance is $11.60–$11.75. The upcoming report could clarify whether new product growth is offsetting pressure on established medicines.
• Negative Sentiment: Patent-cliff concerns are weighing on sentiment: A potential approximately $4 billion revenue exposure in 2027 from patent expirations is viewed as more important than the next quarter’s EPS alone. This concern has contributed to recent weakness ahead of earnings. Johnson & Johnson Stock Fell Nearly 6% in 4 Days Before Its October 13 Earnings
• Negative Sentiment: JNJ underperformed the broader market: The latest decline, occurring while the market advanced, suggests investors are applying company-specific pressure—likely reflecting patent-risk concerns and the need for continued growth to justify JNJ’s premium valuation. Johnson & Johnson Stock Drops Despite Market Gains

Insider Activity

In related news, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president directly owned 16,994 shares of the company's stock, valued at approximately $4,367,458. This represents a 48.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of the firm's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.